Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic:A Scoping Review
| Autor: | Helen Lambert, Hexing Wang, Ak Narayan Poudel, Guiqing Yao, Nour Alhusein, Wenjuan Cong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.drug_class clinical justification Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Secondary infection Antibiotics Review RM1-950 Biochemistry Microbiology Antibiotic prescribing antibiotic use Internal medicine Pandemic Severity of illness Medicine Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics business.industry Covid19 COVID-19 patients secondary infections Infectious Diseases Antimicrobial use disease severity Therapeutics. Pharmacology business |
| Zdroj: | Cong, W, Poudel, A N, Alhusein, N, Wang, H, Yao, G & Lambert, H 2021, ' Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic : A Scoping Review ', Antibiotics, vol. 10, no. 6, 745 . https://doi.org/10.3390/antibiotics10060745 Antibiotics, Vol 10, Iss 745, p 745 (2021) Antibiotics University of Bristol-PURE |
| DOI: | 10.3390/antibiotics10060745 |
| Popis: | This scoping review provides new evidence on the prevalence and patterns of global antimicrobial use in the treatment of COVID-19 patients; identifies the most commonly used antibiotics and clinical scenarios associated with antibiotic prescribing in the first phase of the pandemic; and explores the impact of documented antibiotic prescribing on treatment outcomes in COVID-19 patients. The review complies with PRISMA guidelines for Scoping Reviews and the protocol is registered with the Open Science Framework. In the first six months of the pandemic, there was a similar mean antibiotic prescribing rate between patients with severe or critical illness (75.4%) and patients with mild or moderate illness (75.1%). The proportion of patients prescribed antibiotics without clinical justification was 51.5% vs. 41.9% for patients with mild or moderate illness and those with severe or critical illness. Comparison of patients who were provided antibiotics with a clinical justification with those who were given antibiotics without clinical justification showed lower mortality rates (9.5% vs. 13.1%), higher discharge rates (80.9% vs. 69.3%), and shorter length of hospital stay (9.3 days vs. 12.2 days). In the first 6 months of the pandemic, antibiotics were prescribed for COVID-19 patients regardless of severity of illness. A large proportion of antibiotic prescribing for mild and moderate COVID-19 patients did not have clinical evidence of a bacterial co-infection. Antibiotics may not be beneficial to COVID-19 patients without clinical evidence of a bacterial co-infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|